Evidence map›Paper›PMID 28209904›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017

Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease.

Catharina H M J Van Elssen, Mohammad Rashidian, Vladimir Vrbanac, Kai W Wucherpfennig, Zeina El Habre, Jana Sticht, Christian Freund, Johanne T Jacobsen, Juanjo Cragnolini, Jessica Ingram and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Molecular Imaging of Acute Graft-Versus-Host Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Single-Domain Antibody Theranostics on the Horizon.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  18. Article
  19. Review
  20. ImmunoPET of CD38 with a radiolabeled nanobody: promising for clinical translation.European journal of nuclear medicine and molecular imaging · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 4 countries.

Catharina H M J Van ElssenDivision of Hematology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Mohammad RashidianWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Vladimir VrbanacRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zeina El HabreProtein Engineering Group, Leibniz Institute for Molecular Pharmacology and Freie Universität Berlin, Berlin, Germany.
Jana StichtProtein Engineering Group, Leibniz Institute for Molecular Pharmacology and Freie Universität Berlin, Berlin, Germany.
Christian FreundProtein Engineering Group, Leibniz Institute for Molecular Pharmacology and Freie Universität Berlin, Berlin, Germany.
Johanne T JacobsenWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Juanjo CragnoliniWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Jessica IngramWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Loes PlaisierLaboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; and.
Eric SpieringsLaboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; and.
Andrew M TagerRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts.
Hidde L PloeghWhitehead Institute for Biomedical Research, Cambridge, Massachusetts ploegh@wi.mit.edu.
Freie Universität Berlin · DEMassachusetts Institute of Technology · USUniversity Medical Center Utrecht · NLWhitehead Institute for Biomedical Research · USHarvard University · USMaastricht University · NLMassachusetts General Hospital · USRagon Institute of MGH, MIT and Harvard · US

Funding

A new strategy to disrupt protein-protein interactions in eukaryotic cells.DP1GM106409 · NIGMS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI PLOEGH, HIDDE L. · 2012 to 2016
$4.8M
Sortase-mediated protein engineering for the study of host-pathogen interactionsR01AI087879 · NIAID · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI PLOEGH, HIDDE L. · 2010 to 2019
$4.5M
NIAID NIH HHS R01 AI087879NIGMS NIH HHS DP1 GM106409
6 · The paper itself

Abstract

The immune system plays a crucial role in many diseases. Activation or suppression of immunity is often related to clinical outcome. Methods to explore the dynamics of immune responses are important to elucidate their role in conditions characterized by inflammation, such as infectious disease, cancer, or autoimmunity. Immuno-PET is a noninvasive method by which disease and immune cell infiltration can be explored simultaneously. Using radiolabeled antibodies or fragments derived from them, it is possible to image disease-specific antigens and immune cell subsets.

Indexed as

AnimalsGraft vs Host DiseaseHistocompatibility Antigens Class IIHumansImmunity, InnateMiceMice, KnockoutPositron-Emission TomographyRadiopharmaceuticalsSingle-Domain AntibodiesT-LymphocytesHistocompatibility Antigens Class IIRadiopharmaceuticalsSingle-Domain AntibodiesGvHDhumanized miceImmunoPETsingle domain antibodies

Identifiers

PMID28209904
PMCPMC5450362
OpenAlexW2588012190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.